Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 339,967 shares of the biopharmaceutical company's stock after buying an additional 27,572 shares during the period. NewEdge Wealth LLC's holdings in Gilead Sciences were worth $27,541,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at $25,000. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 241 shares during the last quarter. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the third quarter worth about $26,000. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new position in Gilead Sciences in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company's stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the transaction, the chief financial officer now owns 101,534 shares of the company's stock, valued at $8,709,586.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,000 shares of company stock valued at $721,180. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating on the stock in a research note on Monday, March 4th. Barclays dropped their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday, February 12th. Truist Financial cut shares of Gilead Sciences from a "buy" rating to a "hold" rating and reduced their target price for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Mizuho dropped their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, February 22nd. Finally, Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating for the company in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Hold" and an average target price of $85.36.

Gilead Sciences Price Performance

GILD traded down $0.58 during trading on Friday, reaching $68.07. 5,691,432 shares of the stock were exchanged, compared to its average volume of 7,375,738. Gilead Sciences, Inc. has a 1 year low of $67.62 and a 1 year high of $87.86. The company has a market capitalization of $84.75 billion, a price-to-earnings ratio of 15.13, a P/E/G ratio of 0.89 and a beta of 0.19. The business's 50 day moving average price is $72.97 and its two-hundred day moving average price is $76.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to analysts' expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. Gilead Sciences's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.67 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.85 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.52%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences's payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.